| Audience | Patients, clinicians, caregivers, and cannabis-medicine readers |
| Primary Topic | Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Cannabis Use and Cannabis Use Disorder in Early-Onset Psychosis. |
| Source | Read the full study |
Cannabis Science Evidence Report: Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Cannabis Use and Cannabis Use Disorder i
To quantify the prevalence of cannabis use (CU) and cannabis use disorders (CUD) in Early-Onset Psychosis (EOP; <18 years) and examine their correlates, clinical and functional impact. This PRISMA-compliant systematic review and meta-analysis (CRD420251070701) searched six databases until 1/7/2025, for studies evaluating CU/CUD in EOP. Data were extracted by independent researchers, and quality assessment was conducted using the Newcastle-Ottawa Scale. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A narrative synthesis was conducted. Forty studies (N=3,473; age=16.2±1.6 years; male=59%) were included. In EOP, pooled prevalence was for current CU 32.8... The practical question is not whether this source is interesting, but how much clinical weight it can safely carry.
| Evidence Lane | Clinical Evidence Update |
| Study Type | Journal Article |
| Population | Verify from primary source |
| Exposure or Intervention | Verify from primary source |
| Comparator | Verify from primary source |
| Primary Outcomes | Verify from primary source |
| Journal or Source | Journal of the American Academy of Child and Adolescent Psychiatry |
| Published | 2026Jun22 |
| PMID | 42331312 |
| DOI | 10.1016/j.jaac.2026.06.012 |
| Important Limitation | The discovery record alone is not enough to make strong clinical claims. |
To quantify the prevalence of cannabis use (CU) and cannabis use disorders (CUD) in Early-Onset Psychosis (EOP; <18 years) and examine their correlates, clinical and functional impact. This PRISMA-compliant systematic review and meta-analysis (CRD420251070701) searched six databases until 1/7/2025, for studies evaluating CU/CUD in EOP. Data were extracted by independent researchers, and quality assessment was conducted using the Newcastle-Ottawa Scale. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A narrative synthesis was conducted. Forty studies (N=3,473; age=16.2±1.6 years; male=59%) were included. In EOP, pooled prevalence was for current CU 32.8...
The first clinical task is to identify what was actually measured, who was included, and whether the source can support the claim readers may want to draw from it.
Cannabis medicine needs evidence that connects mechanisms and real patient outcomes without blurring the difference between possibility and proof.
This item appears relevant because it touches a question patients or clinicians may reasonably ask in practice.
The safest reading keeps the evidence lane visible. Preclinical, observational, protocol, review, and randomized evidence do not answer the same clinical question.
Any missing information about comparator, population, dose, route, outcome ascertainment, funding, or adverse events should lower confidence until verified.
The responsible translation is to use the source as context for better questions, not as a substitute for individualized clinical care.
A clinician-facing reading should preserve uncertainty, avoid causal overreach, and name the next evidence step that would make the signal more useful.
Cannabis medicine sits at the intersection of patient experience, mechanistic plausibility, clinical trials, observational research, and public health caution.
The most useful CED Clinic interpretation keeps those evidence layers separate while helping readers understand why the source is worth attention.
That balance is the point of the home LLM workflow: local models can draft and structure, while validation gates protect the clinical boundary.
I would read this as a signal that deserves careful attention, not as a shortcut to a clinical conclusion.
The useful question is what this source helps us ask more precisely, and where the evidence still needs a stronger design before it changes care.
How to Read This Cannabis Evidence Without Overstating It
The safest reading starts by separating what the source reports from what it proves.
That discipline is especially important in cannabis medicine, where public enthusiasm can outrun the evidence.
A Better Reading Order
Start with the study design
Identify whether this is randomized, observational, preclinical, a protocol, a review, or a policy source.
Find the comparator
Ask what the cannabis exposure was compared against, because comparator choice determines the strength of interpretation.
Check patient relevance
Look for population, dose, route, outcomes, adverse events, and follow-up before translating the finding.
Separate signal from advice
A signal can justify better questions without becoming a recommendation for an individual patient.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated.
What Patients Can Safely Take From This
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
How a Clinician Might Use This
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
Where the Evidence Can Be Overread
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
What the Design Still Needs
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
How It Fits the Broader Evidence
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
What Would Need Monitoring
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
What Better Evidence Should Test
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
What Not to Claim
This lens keeps the source useful while preserving the boundary between an interesting signal and a clinical conclusion.
The practical value is strongest when the reader keeps design, population, comparator, outcomes, and safety details visible.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Does this source prove cannabis works for this condition?
Not by itself. The strength of the claim depends on the primary source design, comparator, population, and outcomes.
Can patients use this as medical advice?
No. This is educational interpretation and should not replace individualized clinical care.
Why does study design matter so much?
Design determines whether a source can support causation, association, mechanism, or only a hypothesis.
What should clinicians look for first?
Clinicians should start with population, intervention or exposure, comparator, outcomes, adverse events, and follow-up.
What if the finding is preclinical?
Preclinical findings may explain mechanisms, but they should not be treated as proof of patient benefit.
What if the finding is observational?
Observational findings can be clinically useful, but confounding and selection effects must stay visible.
How should safety be interpreted?
Safety needs route, dose, population, duration, and adverse-event capture before it can be generalized.
Does this identify the best product or dose?
No. A source usually cannot identify an optimal product or dose unless it directly tested that question.
Why include related CED Clinic reading?
Related reading helps readers compare this source with earlier coverage and avoid interpreting one item in isolation.
What is the main takeaway?
The main takeaway is to read Systematic Review and Meta-Analysis: Prevalence, Correlates, and Impact of Canna with curiosity and restraint.
